• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Holdings
Company Encyclopedia
View More
name
Rayliant Quantamental China Equity ETF
RAYC.US
Shareholder
Ownership%OwnedShare ChgReport Date
No Data
News
View More

China’s EV battery giants wade into shipbuilding to bolster Beijing’s dominance

China's leading EV battery makers, CATL and Gotion High-tech, are expanding into shipbuilding to support Beijing's dominance in the industry. CATL plans to launch a pure electric vessel in three years, while Gotion's battery packs power a ship with 132 standard containers. China's shipbuilding firms held 65% of global orders in 2025. The US and South Korea are also increasing efforts in shipbuilding. Jiangnan Shipyard plans to build the world's first nuclear-powered container vessel by 2035.

南华早报·Yesterday at 09:05
SZ
300750
+0.72%
HK
03750
+1.57%
南华早报·Yesterday at 09:05
SZ
300750
+0.72%
HK
03750
+1.57%

The stock market "long-term buyers" are taking shape

The channel for Chinese insurance funds to increase their allocation to A-shares is being systematically opened up. With the continuous growth of life insurance premiums, it is gradually becoming a stable "supply line" of long-term capital for the A-share market

Wallstreetcn·12/13/2025 09:19
SH
601336
+1.37%
HK
01336
-0.49%
SH
601601
+2.05%
Wallstreetcn·12/13/2025 09:19
SH
601336
+1.37%
HK
01336
-0.49%
SH
601601
+2.05%
© 2025 Longbridge|Disclaimer

Schedules & Filings

Schedules
Filings
Nov28
Distribution Plan(EST)

Cash dividend 0.3575 USD

Nov26
Distribution Plan(EST)

Cash dividend 0.3575 USD

Distribution Plan(EST)

Cash dividend 0.3575 USD

View More

Event Tracking

Dec14
CPIC P&C Customizes Insurance Services for Jiusi Smart
07:26
Dec13
2025 National Medical Insurance Drug Directory Update, Hengrui and Eli Lilly are Major Winners
03:47
Dec12
CPIC Shares Experience in Asset-Liability Management Under Low Interest Rates
12:09
Hengrui Medicine's Subsidiary Receives Clinical Trial Approval Notice for RSS0343 Tablets from NMPA
11:57
HRS9531 Injection Approved for Clinical Trials by Huahai Medicine's Subsidiary
11:53
China Chengtong and China Merchants Bank Sign Strategic Cooperation Agreement
11:33